CPC C07H 19/20 (2013.01) [A61K 31/7076 (2013.01); A61P 11/00 (2018.01); A61P 11/06 (2018.01); A61P 35/00 (2018.01); A61K 39/00 (2013.01)] | 14 Claims |
1. A method for treating a disease or disorder amenable to treatment by activation of NFkB, p38, and JNK cell signaling pathways in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound selected from:
or a stereoisomer, stable isotope, prodrug or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from tuberculosis, meningitis, pneumonia, ulcer, sepsis, rhinitis, asthma, allergy, chronic obstructive pulmonary disease (COPD), cancer, inflammatory bowel disease, arthritis, obesity, radiation-induced inflammation, psoriasis, atopic dermatitis, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, systemic lupus, erythematosus (SLE), autoimmune thyroiditis (Grave's disease), multiple sclerosis, ankylosing spondylitis bullous diseases, actinic keratoses, ulcerative colitis, Crohn's disease, alopecia areata, and diseases and disorders caused by the hepatitis C virus (HCV), the hepatitis B virus (HBV), or the human immunodeficiency virus (HIV).
|